NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2] Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval by the US FDA[3] Australian-led research played key role in the development of NIKTIMVO, a first-in-class novel colony stimulating factor-1 receptor (CSF-1R) blocking antibody.[1],[4] SINGAPORE, May 3, 2026 /PR

– Publication reports favorable safety, tolerability, and device performance, while highlighting posteriorly directed drug distribution as visualized by thermal imaging – TEL AVIV, Israel, May 3, 2026 /PRNewswire/ -- Everads Therapy, a clinical-stage company leveraging its novel suprachoroidal delivery technology to advance the treatment of retinal diseases, today announced publication of clinical data from its first-in-human trial in Ophthalmology Science, the peer-reviewed journal of the Ameri

New Preclinical Data Show Tazbentetol Reduces Retinal Cell Loss and Preserves Visual Function in Glaucoma and Diabetic Retinopathy Models LOS ANGELES, May 3, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, will present this week the results of two new preclinical studies demonstrating the neuroprotective effects of tazbentetol (SPG302) in glaucoma and diabetic r

GUANGZHOU, China, May 3, 2026 /PRNewswire/ -- The 139th China Import and Export Fair (Canton Fair) has rolled out nine newly established product zones. Phase 3 features an expanded and upgraded Intelligent Healthcare zone and the inaugural presentation of a Functional & Technical Fabrics zone. Continue Reading The upgraded Intelligent Healthcare zone brings together 50 companies presenting a full spectrum of intelligent medical solutions, spanning AI-powered diagnostics, surgical robotics, and n

BRUSSELS, May 3, 2026 /PRNewswire/ -- Smartee Denti-Technology, a global innovator in clear aligner solutions, presented its latest clinical developments and detailed its European localization strategy at the 7th Congress of the European Aligner Society (EAS). Held from April 16 to 18, at the SQUARE – Brussels Convention Centre, the congress marked the society's 10th anniversary and brought together over 1,000 participants from 65 countries under the theme "Aligner Next Generation". Continue R

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia Researchers will present additional data from studies of VOXZOGO for hypochondroplasia, ahead of pivotal topline Phase 3 data expected in the first half of 2026 SAN RAFAEL, Calif., May 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new research fr

RIYADH, SAUDI ARABIA, May 2, 2026 / EINPresswire.com / -- Advanced cancer care does not fail at the point of discovery; it often fails at the point of distribution. The challenge is not only developing specialized treatments, but ensuring they reach patients in time. At King Faisal Specialist Hospital and Research Centre, part of the response has taken the form of an operational model that extends elements of cancer care beyond the hospital itself, into a distributed national network designed to

CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospective

RIYADH, SAUDI ARABIA, May 1, 2026 / EINPresswire.com / -- As the Milken Institute Global Conference opens May 3 in Los Angeles, King Faisal Specialist Hospital and Research Centre (KFSH) enters the conversation with an approach that positions artificial intelligence not as an adjunct technology, but as a core operational capability shaping how care is delivered, decisions are made, and outcomes are optimized at scale. At the center of this transformation is the integration of data-driven technol

Welcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman took a close look at a make-or-break moment for Bristol Myers Squibb, and Lei Lei Wu and I had updates on Amgen’s ongoing saga over its rare disease drug Tavneos. Meanwhile, Andrew Dunn reported from one of the world’s largest AI research gatherings, I attended Supreme Court arguments in a patent case that’s being closely watched by the